Your browser doesn't support javascript.
loading
Show: 20 | 50 | 100
Results 1 - 4 de 4
Filter
Add more filters










Database
Language
Publication year range
1.
Biophys Chem ; 228: 69-80, 2017 09.
Article in English | MEDLINE | ID: mdl-28711675

ABSTRACT

T-2410 and T-2429 are HIV fusion inhibitor peptides (FI) designed to present a higher efficiency even against HIV strains that developed resistance against other FIs. Similar peptides were shown to interact with model membranes both in the liquid disordered phase and in the liquid ordered state. Those results indicated that such interaction is important to function and could be correlated with their effectiveness. Extensive molecular dynamics simulations were carried out to investigate the interactions between both T-2410 and T-2429 with bilayers of pure 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC) and a mixture of POPC/cholesterol (Chol) (1:1). It was observed that both peptides interact strongly with both membrane systems, especially with the POPC/Chol systems, where these peptides show the highest number of H-bonds observed so far. T-2410 and T-2429 showed higher extent of interaction with bilayers when compared to T-20 or T-1249 in previous studies. This is most notable in POPC/Chol membranes where, although able to form H-bonds with Chol, they do so to a lesser extent than T-1249 does, the latter being the only FI peptide so far that was observed to form H-bonds with Chol. This behavior suggests that interaction of FI peptides with rigid Chol rich membranes may not be as dependent from peptide/Chol H-bond formation as previous results of T-1249 behavior led to believe. As in other similar peptides, the higher ability to interact with membranes shown by T-2410 and T2429 is probably correlated with its higher inhibitory efficiency.


Subject(s)
HIV Fusion Inhibitors/chemistry , Lipid Bilayers/chemistry , Molecular Dynamics Simulation , Amino Acid Sequence , Cholesterol/chemistry , HIV/drug effects , HIV Fusion Inhibitors/metabolism , HIV Fusion Inhibitors/pharmacology , Humans , Hydrogen Bonding , Lipid Bilayers/metabolism , Molecular Sequence Data , Peptides/chemistry , Peptides/metabolism , Peptides/pharmacology , Phosphatidylcholines/chemistry , Protein Structure, Secondary , Sequence Alignment , Thermodynamics
2.
Comput Math Methods Med ; 2012: 151854, 2012.
Article in English | MEDLINE | ID: mdl-22675399

ABSTRACT

T-1249 is a peptide that inhibits the fusion of HIV envelope with the target cell membrane. Recent results indicate that T-1249, as in the case of related inhibitor peptide T-20 (enfuvirtide), interacts with membranes, more extensively in the bilayer liquid disordered phase than in the liquid ordered state, which could be linked to its effectiveness. Extensive molecular dynamics simulations (100 ns) were carried out to investigate the interaction between T-1249 and bilayers of 1-palmitoyl-2-oleoyl-phosphatidylcholine (POPC) and POPC/cholesterol (1 : 1). It was observed that T-1249 interacts to different extents with both membrane systems and that peptide interaction with the bilayer surface has a local effect on membrane structure. Formation of hydrogen bonding between certain peptide residues and several acceptor and donor groups in the bilayer molecules was observed. T-1249 showed higher extent of interaction with bilayers when compared to T-20. This is most notable in POPC/Chol membranes, owing to more peptide residues acting as H bond donors and acceptors between the peptide and the bilayer lipids, including H-bonds formed with cholesterol. This behavior is at variance with that of T-20, which forms no H bonds with cholesterol. This higher ability to interact with membranes is probably correlated with its higher inhibitory efficiency.


Subject(s)
HIV Envelope Protein gp41/chemistry , HIV Envelope Protein gp41/pharmacology , HIV Fusion Inhibitors/chemistry , HIV Fusion Inhibitors/pharmacology , HIV-1/drug effects , Peptide Fragments/chemistry , Peptide Fragments/pharmacology , Cholesterol/chemistry , HIV-1/pathogenicity , HIV-1/physiology , Humans , Hydrogen Bonding , Lipid Bilayers/chemistry , Models, Molecular , Molecular Dynamics Simulation , Phosphatidylcholines/chemistry , Virus Internalization/drug effects
3.
Bioresour Technol ; 102(17): 7827-34, 2011 Sep.
Article in English | MEDLINE | ID: mdl-21745739

ABSTRACT

Phytoremediation technologies such as constructed wetlands have shown higher efficiencies in removal of pharmaceuticals from wastewaters than conventional wastewater treatment processes, and plants seem to have an important role in the removal of some of those compounds. In this context, a study was conducted to assess tolerance, uptake, and metabolism of the epilepsy drug, carbamazepine, by the macrophyte Typha spp. This evaluation was conducted in hydroponic solutions with 0.5-2.0mg/L of this pharmaceutical for a maximum period of 21 days. The removal of carbamazepine from nutrient solutions by the plants reached values of 82% of the initial contents. Furthermore, a metabolite (10,11-dihydro-10,11-epoxycarbamazepine) was detected in leaf tissues indicating carbamazepine translocation and metabolism inside plants. Activities of antioxidant enzymes catalase, superoxide dismutase, and guaiacol peroxidase generally increase (after some mild initial inhibition in the case of the latter enzyme) as result of the abiotic stress caused by the exposure to carbamazepine, but ultimately Typha seemed able to cope with its toxicity. The results obtained in this study suggest the ability of Typha spp., to actively participate in the removal of carbamazepine from water when used in phytotreatment systems.


Subject(s)
Anticonvulsants/metabolism , Biodegradation, Environmental , Carbamazepine/metabolism , Typhaceae/metabolism , Water Pollutants, Chemical/metabolism , Chromatography, Liquid , Spectrometry, Mass, Electrospray Ionization , Tandem Mass Spectrometry
4.
J Pept Sci ; 14(4): 442-7, 2008 Apr.
Article in English | MEDLINE | ID: mdl-18069719

ABSTRACT

Fusion of the HIV envelope with the target cell membrane is a critical step of the HIV entry into the target cell. Several peptides based on the C-region of HIV gp41 have been used in clinical trials as possible HIV fusion inhibitors. Among these are T-1249 and T-20 (also known as enfurvitide). Despite recent works, a detailed molecular picture of the inhibitory mechanism of these molecules is still lacking. These peptides are usually depicted as alpha-helices by analogy with the structure of the sequence of the gp41 protein with which they are homologous. However, structures like these would be highly unstable in solution and thus would not explain, by themselves, the ability that the two fusion inhibitors have to become solvated by water and also interact effectively with cell membranes. To this effect, extensive molecular dynamics simulations were carried out to investigate the structure and conformational behavior of T-1249 and T-20 in water, as well as shorter homologous peptides CTP and 3f5, which show no inhibitory action. We found that the studied inhibitors have no stable structure in solution in the time scale studied. Additionally, the solvent accessible area varies significantly during the simulation. Our findings suggest that these peptides may assume not only one, but several possible sets of structures in solution, some of which more adequate to interact with the solvent, whereas others might be better suited to interact with cell membranes. Interestingly, and in accordance with published experimental studies, we verified that T-1249 displays considerably larger alpha-helical structure than T-20. Taking into account a recent study with design peptides with increased helicity, it is possible that this feature may be related to the increased inhibiting efficiency of T-1249 relative to that of T-20.


Subject(s)
HIV Envelope Protein gp41/chemistry , HIV Fusion Inhibitors/chemistry , HIV-1/drug effects , Peptide Fragments/chemistry , Amino Acid Sequence , Computer Simulation , Enfuvirtide , HIV Envelope Protein gp41/pharmacology , HIV Fusion Inhibitors/pharmacology , Humans , Molecular Conformation , Molecular Sequence Data , Peptide Fragments/pharmacology , Protein Structure, Secondary , Solutions
SELECTION OF CITATIONS
SEARCH DETAIL
...